News
-
-
PRESS RELEASE
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Aspire's sublingual aspirin formulation rapidly inhibits blood clotting by blocking platelet aggregation, showing potential for accelerated approval in Q3 2025 -
-
PRESS RELEASE
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
Aspire's BUZZ BOMB™ sublingual pre-workout supplement with 50mg of caffeine in four flavors showcased at FitCon and FitExpo, impressing fitness experts and consumers for its rapid delivery technology and convenience
